All News

Best Rheumatologists (7.19.2024) Dr. Jack Cush reviews the news and journal reports of interesting, including irAE, pollution and Psoriasis, microwave therapy, scleroderma without scleroderma that only the best rheumatologists could discern. https://t.co/2Tkdat6CXv https://t.co/1lOfbgNZvn

Links:

Dr. John Cush RheumNow ( View Tweet)
Updated EULAR Recommendations on the Treatment of Systemic Sclerosis Medscape has published an overview to the 2024 updated recommendations for the treatment of SSc presented in Vienna at EULAR 2024. https://t.co/rmBIfNzJcu https://t.co/uZ2JUdsecZ

Links:

Dr. John Cush RheumNow ( View Tweet)
Systemic sclerosis sine scleroderma Systemic sclerosis sine scleroderma (ssSSc), which accounts for nearly 10% of systemic sclerosis (SSc) patients and was first described in 1962, is a subset of SSc. https://t.co/5NMykTHEtK https://t.co/JNo27zaTrJ

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast square

Best Rheumatologists (7.19.2024)

d Jack Cush, MD

This week on the RheumNow Podcast, Dr. Jack Cush reviews the news and journal reports of interesting, including irAE, pollution and Psoriasis, microwave therapy, scleroderma without scleroderma that only the best rheumatologists could discern.

Read Article
PSS.scleroderma.arthritis.contractures

Updated EULAR Recommendations on the Treatment of Systemic Sclerosis

d Medscape

Medscape has published an overview to the 2024 updated recommendations for the treatment of systemic sclerosis (SSc) presented in Vienna at EULAR 2024 by Professor Francesco Del Galdo, MD, PhD on behalf of a 27 member task force.

Read Article
scleroderma,month,organ,heart

Systemic sclerosis sine scleroderma

d Jack Cush, MD

Systemic sclerosis sine scleroderma (ssSSc), which accounts for nearly 10% of systemic sclerosis (SSc) patients and was first described in 1962, is a subset of SSc.

Read Article
Dead Words Eulogy Cover Image

ICYMI: Dead Words Eulogy

d Jack Cush, MD

The trouble with rheumatology may be the words we live by. Welcome to the eulogy for rheumatology 'dead words'. We're here today to celebrate the loss of rheumatology past. These are dead words in rheumatology, words fortified unfortunately by history and habit. The lexicon of rheumatology is unique, it's challenging and it's mostly incomprehensible to those who don't know...but those are the cornerstones of the greatest of medical subspecialties. 

Read Article
EUSTAr study of 4431 systemic sclerosis (SSc) pts - anti-SSA antibodies are detected in 15% of SSc-patients and represent an independent risk factor for the presence of lung fibrosis (OR 1.24) & more severe lung involvement. #EULA2024 OP0013 https://t.co/NcxReWk83n https://t.co/FSMx22XiNo

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast square

Future Big BiTEs (6.28.2024)

d Jack Cush, MD

Dr. Jack Cush reviews the news, journal articles and regulatory announcements from the past week on RheumNow.com.

Read Article
Finnish study of 331 systemic sclerosis (SSc) pts found that SSc is the major cause of death in diffuse & limited SSc. Among 91 deaths, the 5 & 10 year survival was 88% and 80%. Most common cause death was SSc (n=35)& ILD (13). https://t.co/m30CoAdsMN https://t.co/Ms9LN7eAUK

Links:

Dr. John Cush RheumNow ( View Tweet)
EUSTAr study of 4431 systemic sclerosis (SSc) pts - anti-SSA antibodies are detected in 15% of SSc-patients and represent an independent risk factor for the presence of lung fibrosis (OR 1.24) & more severe lung involvement. #EULA2024 OP0013 https://t.co/oW6NBjIG7E https://t.co/toyvHxJlr9

Links:

Dr. John Cush RheumNow ( View Tweet)
Rituximab vs. Tocilizimab for Scleroderma: Which is Better? Dr. Janet Pope discusses abstract OP0295 presented at Eular 2024 in Vienna, Austria. https://t.co/70YF2wxwj5 https://t.co/8BHCafFs3u

Links:

Dr. John Cush RheumNow ( View Tweet)
New Treatments for Systemic Sclerosis aHSCT for SSc has been proven the most effective treatment strategy with regard to overall and event free survival in selected patients.2 But a key limitation is its toxicity, and new treatment options are needed. https://t.co/xUI0plrk42 https://t.co/DqGUhU6D1Z

Links:

Dr. John Cush RheumNow ( View Tweet)
pssfing.jpg

New Treatments for Systemic Sclerosis

d EurekAlert!

Autologous hematopoietic stem cell transplantation (aHSCT) for SSc has been proven the most effective treatment strategy with regard to overall and event free survival in selected patients.2 But a key limitation is its toxicity, and new treatment options are needed.

Read Article
#Scleroderma updated #EULAR2024 #recommendations @eular_org SKIN Are they good enough? Great work by task force @EUSTAR_org Do we alter initial Rx if v high mRSS? Ex #MMF not much improvement on skin vs #RTX #Cyclo Or combo Rx? We need to improve #SoC ?CAR-T ? RCT @RheumNow https://t.co/WhEzDdjVeu

Links:

Janet Pope Janetbirdope ( View Tweet)
#Scleroderma updated #EULAR2024 #recommendations @eular_org Are they good enough? Great work by task force @EUSTAR_org #PAH my thoughts Where does #sotaracept in #PAH fit in Not mentioned ?#selexipag before #epoprostenol For sure there is country variant @RheumNow https://t.co/3dJ6eusSkU

Links:

Janet Pope Janetbirdope ( View Tweet)
Agree! Liz Volkmann said it straight Unsustainable RCTs in ILD trials in #scleroderma Why Can’t recruit ~same pool of early #dcSSc design RCT UNETHICAL a to have a progressing #scleroderma-ILD Pt on failed background #MMF + placebo for 1 yr 🙏🏻 #EULAR2024 @RheumNow @eular_org https://t.co/29oFEazwmM

Links:

Janet Pope Janetbirdope ( View Tweet)
#EULAR2024 OP0295 Approriate patient stratification matters in trials. H2H RCT of Tocilizumab vs Rituximab in refractory #SSc-ILD (failed CyC), stratified based on RNA-seq of lungs biopsy showed improved efficacy in TCZ with low B-cell lineage expression signature @RheumNow https://t.co/7ME3Bd2PeM

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2024 OP0288 Patients with Scleroderma shouldn’t be excluded from Lung Transplantation because of a concern with post-surgery complications/long term complications. Data from Italy of N=13 pts showed 93% survival, improved disesase activity & FVC over 2 years @RheumNow https://t.co/zPFB1MFxdc

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2024 OP0256 Phase 2 RCT ReSScue data of fecal microbiota transplantation did not meet primary endpoint (bloating & diarrhoea) in scleroderma. How about impact on faecal incontinence symptoms? This improved throughout 20wks. Could be due improved stool consistency @RheumNow https://t.co/1t7d3M5S4Z

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.